Tags

Type your tag names separated by a space and hit enter

GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype.
J Infect Dis. 2006 Aug 15; 194(4):410-9.JI

Abstract

BACKGROUND

Persistent GB virus C (GBV-C) coinfection leads to slower human immunodeficiency virus (HIV) progression. Despite the existence of multiple GBV-C genotypes, their relevance to the progression of HIV disease is unknown. We therefore investigated (1) the prevalence and genotype of GBV-C in hepatitis C virus (HCV)/HIV-coinfected patients and (2) the impact of HCV treatment on GBV-C RNA clearance.

METHODS

We retrospectively studied 130 HCV/HIV-coinfected patients initiating HCV therapy. Anti-E2 enzyme-linked immunosorbent assay, reverse-transcription polymerase chain reaction (PCR), and real-time PCR were used to detect and quantify GBV-C infection. GBV-C genotype was determined by sequencing the 5' untranslated region.

RESULTS

GBV-C infection (past or current) was identified in 111 (85%) of the patients. Ongoing GBV-C replication was detected in 40 patients. Coinfection with GBV-C genotype 2 was associated with significantly higher CD4(+) cell counts. After 24 weeks of HCV therapy, GBV-C RNA clearance was observed in 50% of patients, although this was not associated with changes in HIV load or with CD4(+) cell counts. Sustained GBV-C RNA clearance was observed in 31% of patients with GBV-C RNA detected at baseline.

CONCLUSIONS

GBV-C coinfection was extremely common. GBV-C RNA clearance with HCV therapy was associated with neither short-term loss of HIV control nor impaired immune status. The association of GBV-C genotype 2 with higher CD4(+) cell counts merits further study.

Authors+Show Affiliations

Department of Internal Medicine I, University of Bonn, Bonn, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16845623

Citation

Schwarze-Zander, Carolynne, et al. "GB Virus C (GBV-C) Infection in Hepatitis C Virus (HCV)/HIV-coinfected Patients Receiving HCV Treatment: Importance of the GBV-C Genotype." The Journal of Infectious Diseases, vol. 194, no. 4, 2006, pp. 410-9.
Schwarze-Zander C, Blackard JT, Zheng H, et al. GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis. 2006;194(4):410-9.
Schwarze-Zander, C., Blackard, J. T., Zheng, H., Addo, M. M., Lin, W., Robbins, G. K., Sherman, K. E., Zdunek, D., Hess, G., & Chung, R. T. (2006). GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. The Journal of Infectious Diseases, 194(4), 410-9.
Schwarze-Zander C, et al. GB Virus C (GBV-C) Infection in Hepatitis C Virus (HCV)/HIV-coinfected Patients Receiving HCV Treatment: Importance of the GBV-C Genotype. J Infect Dis. 2006 Aug 15;194(4):410-9. PubMed PMID: 16845623.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. AU - Schwarze-Zander,Carolynne, AU - Blackard,Jason T, AU - Zheng,Hui, AU - Addo,Marylyn M, AU - Lin,Wenyu, AU - Robbins,Gregory K, AU - Sherman,Kenneth E, AU - Zdunek,Dietmar, AU - Hess,Georg, AU - Chung,Raymond T, AU - ,, Y1 - 2006/07/12/ PY - 2005/12/19/received PY - 2006/02/10/accepted PY - 2006/7/18/pubmed PY - 2006/9/6/medline PY - 2006/7/18/entrez SP - 410 EP - 9 JF - The Journal of infectious diseases JO - J Infect Dis VL - 194 IS - 4 N2 - BACKGROUND: Persistent GB virus C (GBV-C) coinfection leads to slower human immunodeficiency virus (HIV) progression. Despite the existence of multiple GBV-C genotypes, their relevance to the progression of HIV disease is unknown. We therefore investigated (1) the prevalence and genotype of GBV-C in hepatitis C virus (HCV)/HIV-coinfected patients and (2) the impact of HCV treatment on GBV-C RNA clearance. METHODS: We retrospectively studied 130 HCV/HIV-coinfected patients initiating HCV therapy. Anti-E2 enzyme-linked immunosorbent assay, reverse-transcription polymerase chain reaction (PCR), and real-time PCR were used to detect and quantify GBV-C infection. GBV-C genotype was determined by sequencing the 5' untranslated region. RESULTS: GBV-C infection (past or current) was identified in 111 (85%) of the patients. Ongoing GBV-C replication was detected in 40 patients. Coinfection with GBV-C genotype 2 was associated with significantly higher CD4(+) cell counts. After 24 weeks of HCV therapy, GBV-C RNA clearance was observed in 50% of patients, although this was not associated with changes in HIV load or with CD4(+) cell counts. Sustained GBV-C RNA clearance was observed in 31% of patients with GBV-C RNA detected at baseline. CONCLUSIONS: GBV-C coinfection was extremely common. GBV-C RNA clearance with HCV therapy was associated with neither short-term loss of HIV control nor impaired immune status. The association of GBV-C genotype 2 with higher CD4(+) cell counts merits further study. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/16845623/GB_virus_C__GBV_C__infection_in_hepatitis_C_virus__HCV_/HIV_coinfected_patients_receiving_HCV_treatment:_importance_of_the_GBV_C_genotype_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/505713 DB - PRIME DP - Unbound Medicine ER -